Episealer® Talus: Case report with 5-years’ follow-up data accepted for publication
Episurf Medical (NASDAQ: EPIS B) today announces that a case report with 5-years’ follow-up data of the very first Episealer® Talus patient has been accepted for publication in the peer-reviewed scientific journal Foot & Ankle Surgery: Techniques, Reports & Cases (Holz J., Ryd L., Kaiser R., Hollander K., van Dijk N., Schneider S., Treatment of an Osteochondral Lesions of the Talus with a novel Patient-specific Metallic Implant: A Case Report with 5-year Follow-up and Review of the Literature., Foot & Ankle Surgery: Techniques, Reports & Cases, 2021). The publication will appear in volume 1, issue 3, Autumn 2021. Foot & Ankle Surgery: Technique, Reports & Cases is an official publication of the American College of Foot and Ankle Surgeons and publishes the latest advances in cutting-edge surgical techniques for correction of foot and ankle disorders.
In the case report, the authors report on a 33-year old male patient who experienced persistent pain and reduced range of motion following an ankle sprain, and the patient underwent medial talar dome ankle surgery in May 2016 (Hamburg, Germany). The patient was treated with an Episealer® Talus implant, and he was the first patient worldwide to receive this implant. The patient was consequently followed up at 3, 6, 12, 24, 36, 48 and 60 months using the standard subjective outcome measures VAS pain score, Foot and Ankle Outcome Score (FAOS), and sports subscale of the Foot and Ankle Ability Measure (FAAM). The article reports that there was immediate pain relief, and a fast rehabilitation was achieved. Six weeks postoperatively, the patient returned to work. There have not been any limitations in activities of daily living or work-related activities until today and the patient was able to return to his athletic level and started playing soccer again. The authors conclude that the first implantation of this novel patient-specific metal implant for the treatment of focal osteochondral lesions of talus has been highly successful up to five years after implantation.
”Although this is a single patient case report, this article shows that a bespoke metal implant can articulate against joint cartilage over 5 years’ time with excellent results. It works in the ankle and we have previously shown it works in the knee”, says Prof. Leif Ryd, Senior Medical Advisor to Episurf Medical.
The Episealer® Talus implant used in this surgical procedure was performed on a custom-made basis, implying a regulatory exemption to produce an implant before market approval.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:45 CEST on July 16,2021.
Tags: